The search textbox has an autosuggest feature. When you enter three or more characters,
a list of up to 10 suggestions will popup under the textbox. Use the arrow keys
to move through the suggestions. To select a suggestion, hit the enter key. Using
the escape key closes the listbox and puts you back at the textbox. The radio buttons
allow you to toggle between having all search items start with or contain the text
you entered in the search box.
saracatinib
An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and their effects on cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, saracatinib inhibits Src kinase-mediated osteoclast bone resorption. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code name: | | AZD0530 | |
| |||
| Chemical structures: | | 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1- piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-[(tetrahydro- 2H-pyran-4-yl)oxy]quinazolin-4-amine | |
| |||
